We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Two MicroRNAs Are Linked to Lung Cancer

By HospiMedica staff writers
Posted on 27 Mar 2006
A new study shows that the expression pattern of certain microRNAs (miRNAs) is predictive of tumor aggressiveness in some patients with lung cancer. More...


These miRNAs are small segments of genetic material called ribonucleic acid (RNA), whose actions can change the expression of cancer-related genes within a cell and lead to malignancies. A team of researchers identified two miRNAs, "has-mir-155” and "has-let-7a-2” that could be used as prognostic indicators in patients with adenocarcinoma, a malignancy of the mucous glands in the lung. The study was the result of a collaboration among researchers at the Ohio State University Comprehensive Cancer Center (Columbus, Ohio, USA), the Jikei University School of Medicine (Tokyo, Japan), and the Center for Cancer Research at the U.S. National Cancer Institute (NCI, Bethesda, MD, USA). The results of the study appear in the March 2006 issue of the journal "Cancer Cell.”

High levels of "has-mir-155” or low levels of "has-let-7a-2” were associated with poor prognosis in the lung cancer patients. Overexpression of "has-mir-155” or the signaling of the miRNA to change the amount of a protein produced was the most significant indicator of this prognosis, independent of tumor stage. These miRNAs have been identified in other cancers but this is the first time”has-mir-155” has been linked to lung cancer.

Dr. Curtis Harris, chief of the laboratory of human carcinogenesis at NCI and co-leader of the study, noted that "in the future we can use miRNAs and other biological predictors to select patients who may need more-aggressive therapy.” He believes that miRNAs are going to be important biomarkers of not only diagnosis and prognosis, but therapy, as well. However, further testing will be required before these markers can be used for predicting patient outcomes.



Related Links:
Ohio State U. Comprehensive Cancer Center
Jikei University School of Medicine
NCI

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
Silver Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Critical Care Conversion Kit
Adapter+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.